Skip to main content
Betta Pharmaceuticals Co.,Ltd logo

Betta Pharmaceuticals Co.,Ltd — Investor Relations & Filings

Ticker · 300558 ISIN · CNE100002DD9 LEI · 8368009YF4Y6NC7HVB09 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,654 across all filing types
Latest filing 2022-03-17 AGM Information
Country CN China
Listing Shenzhen Stock Exchange 300558

About Betta Pharmaceuticals Co.,Ltd

https://www.bettapharma.com

Betta Pharmaceuticals Co.,Ltd. focuses on the research, development, and commercialization of innovative oncology medications. The organization specializes in targeted therapies, particularly for the treatment of lung cancer and other solid tumors. Its portfolio includes Icotinib, a small-molecule EGFR tyrosine kinase inhibitor, and Ensartinib, an ALK inhibitor designed for non-small cell lung cancer. The company operates a comprehensive R&D infrastructure dedicated to molecular biology, medicinal chemistry, and clinical development. By prioritizing precision medicine, the firm aims to deliver high-quality therapeutic solutions that address complex oncological challenges. Its pipeline encompasses a diverse range of candidates, including small molecules and biologics, aimed at improving patient outcomes through advanced scientific innovation.

Recent filings

Filing Released Lang Actions
关于2022年第一次临时股东大会的提示性公告
AGM Information Classification · 95% confidence The document is a detailed announcement regarding the convening of the 2022 first extraordinary general meeting (临时股东大会) of Betta Pharmaceuticals Co., Ltd. It includes information about the meeting date, voting methods (onsite and online), agenda items, voting instructions, registration procedures, and related attachments such as proxy forms and voting operation guides. There are no financial statements or financial performance data included. The document serves as a notice or reminder to shareholders about the upcoming meeting and how to participate and vote. It is not the actual voting results, nor is it a full annual or interim report, earnings release, or other financial report. It is also not a proxy solicitation statement but a meeting notice with procedural details. Given the content and purpose, this fits best under the category of AGM Information (AGM-R), which covers presentations and materials shared during the Annual General Meeting or similar shareholder meetings, including notices and procedural announcements for such meetings.
2022-03-17 Chinese
关于投资武汉禾元生物科技股份有限公司暨关联交易的补充公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement by 贝达药业股份有限公司 regarding an investment in another company, 武汉禾元生物科技股份有限公司. It details the investment amount, share price, background of the target company, and strategic rationale. The document is relatively short (2765 characters) and focuses on disclosing a specific transaction and related information. It does not contain financial statements, audit information, or detailed financial results. It is not a report like an Annual Report or Interim Report, nor is it a call transcript or management report. It is an announcement about a capital investment transaction, specifically a financing activity involving subscription of new shares (Pre-IPO round). Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2022-03-13 Chinese
关于股东股份质押的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement from a company regarding the pledge of shares by a shareholder. It details the number of shares pledged, the proportion of total shares, pledge start and end dates, and the pledgee. It also includes cumulative pledge information for related shareholders. The document is titled as an announcement and contains no financial statements or detailed financial analysis. It is a regulatory disclosure about shareholder share pledges, which fits the category of Regulatory Filings (RNS) as it does not fit into more specific categories like capital changes or major shareholding notifications, since it focuses on share pledges rather than ownership changes or capital issuance.
2022-03-10 Chinese
关于公司股东增持股份及增持股份计划的公告
Major Shareholding Notification Classification · 100% confidence The document is an announcement regarding a shareholder's increase in shareholding and a plan to further increase shares in the company. It details the shareholder's identity, the number of shares increased, the method of increase, and the future plan for additional share purchases. There is no financial statement, earnings data, or report attached or referenced as being published. The document is a formal disclosure of a shareholder's transaction and plan to increase holdings, which fits the definition of a Major Shareholding Notification (MRQ). The document length is short (2016 characters), and it is not a report publication announcement or certification. Therefore, the appropriate classification is MRQ.
2022-03-08 Chinese
贝达药业：独立董事关于第三届董事会第二十九次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent director's opinion regarding a specific board meeting agenda item related to an investment proposal. It references compliance with regulatory guidelines and company rules, and it is a formal statement of approval by independent directors. The content is focused on board-level governance and approval of a transaction, not a full financial report or earnings release. It is not a report publication announcement or a certification letter but a governance-related document. Therefore, the document fits best under Board/Management Information (MANG), which covers announcements of changes or opinions related to board decisions and management matters.
2022-03-04 Chinese
关于贝伐珠单抗注射液（贝安汀）新增适应症补充申请获得批准的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the approval of a supplemental drug indication by the National Medical Products Administration (NMPA). It details the drug's new approved uses, regulatory approval notices, and potential impact on company revenue. The document is short (1475 characters) and serves as an official announcement of regulatory approval rather than a financial report or detailed presentation. It does not contain financial statements, management discussion, or detailed investor information. Therefore, it fits best into the category of Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2022-03-04 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.